DNA–drug conjugates enable logic-gated drug delivery amplified by hybridization chain reactions
Beck, A., Goetsch, L., Dumontet, C. & Corvaïa, N. Strategies and challenges for the next generation of antibody drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017).
Google Scholar
Fu, Z. W., Li, S. J., Han, S. F., Shi, C. & Zhang, Y. Antibody drug conjugate: the ‘biological missile’ for targeted cancer therapy. Signal Transduct. Tar. 7, 93 (2022).
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641–661 (2023).
Google Scholar
Tsuchikama, K., Anami, Y., Ha, S. Y. Y. & Yamazaki, C. M. Exploring the next generation of antibody-drug conjugates. Nat. Rev. Clin. Oncol. 21, 203–223 (2024).
Google Scholar
Xu, S. Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharm. Res. 32, 3577–3583 (2015).
Google Scholar
Bordeau, B. M., Yang, Y. J. & Balthasar, J. P. Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy. Cancer Res. 81, 4145–4154 (2021).
Google Scholar
Rubahamya, B., Dong, S. & Thurber, G. M. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci. Adv. 10, 1894 (2024).
Google Scholar
Gebauer, M. & Skerra, A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13, 245–255 (2009).
Google Scholar
Löfblom, J. et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 584, 2670–2680 (2010).
Google Scholar
Ståhl, S. et al. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 35, 691–712 (2017).
Google Scholar
Orlova, A. et al. Tumor Imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66, 4339–4348 (2006).
Google Scholar
Feldwisch, J. et al. Design of an optimized scaffold for affibody molecules. J. Mol. Biol. 398, 232–247 (2010).
Google Scholar
Andersson, K. G. et al. Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with Tc using a peptide-based cysteine-containing chelator. Int. J. Oncol. 49, 2285–2293 (2016).
Google Scholar
Da Pieve, C. et al. Efficient radiolabeling of Z affibody molecule for imaging of HER3 positive tumors. Bioconj. Chem. 27, 1839–1849 (2016).
Google Scholar
Han, J. Y. et al. Therapeutic efficacy and imaging assessment of the HER2-targeting chemotherapy drug Z-pemetrexed in lung adenocarcinoma xenografts. Invest. New Drug 38, 1031–1043 (2020).
Google Scholar
Alhuseinalkhudhur, A. et al. Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. EJNMMI Res. 10, 21 (2020).
Google Scholar
Liang, Z. G., Hu, X. W., Hu, H. Y., Wang, P. & Cai, J. Novel small 99-Tc-labeled affibody molecular probe for PD-L1 receptor imaging. Front. Oncol. 12, 1017737 (2022).
Google Scholar
de Souza, A. L. R. et al. Fluorescent affibody molecule administered at a microdose level labels EGFR expressing glioma tumor regions. Mol. Imaging Biol. 19, 41–48 (2017).
Google Scholar
Serwotka-Suszczak, A. M. et al. A conjugate based on Anti-HER2 diaffibody and auristatin E targets HER2-positive cancer cells. Int. J. Mol. Sci. 19, 3676 (2018).
Tsurutani, J. et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, Phase I study in multiple advanced solid tumors. Cancer Discov. 10, 688–701 (2020).
Google Scholar
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. New Engl. J. Med. 382, 610–621 (2020).
Google Scholar
Shitara, K. et al. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer 24, 780–789 (2021).
Google Scholar
Yin, P., Choi, H. M. T., Calvert, C. R. & Pierce, N. A. Programming biomolecular self-assembly pathways. Nature 451, 318–322 (2008).
Google Scholar
Qian, L. & Winfree, E. Scaling up digital circuit computation with DNA strand displacement cascades. Science 332, 1196–1201 (2011).
Google Scholar
Zhang, D. Y. & Seelig, G. Dynamic DNA nanotechnology using strand-displacement reactions. Nat. Chem. 3, 103–113 (2011).
Google Scholar
Dirks, R. M. & Pierce, N. A. Triggered amplification by hybridization chain reaction. Proc. Natl Acad. Sci. USA 101, 15275–15278 (2004).
Google Scholar
Jung, C. & Ellington, A. D. Diagnostic applications of nucleic acid circuits. Acc. Chem. Res. 47, 1825–1835 (2014).
Google Scholar
Koos, B. et al. Proximity-dependent initiation of hybridization chain reaction. Nat. Commun. 6, 7294 (2015).
Google Scholar
Zhao, Y. X., Chen, F., Li, Q., Wang, L. H. & Fan, C. H. Isothermal amplification of nucleic acids. Chem. Rev. 115, 12491–12545 (2015).
Google Scholar
Li, J., Green, A. A., Yan, H. & Fan, C. H. Engineering nucleic acid structures for programmable molecular circuitry and intracellular biocomputation. Nat. Chem. 9, 1056–1067 (2017).
Google Scholar
Chang, X. et al. Construction of a multiple-aptamer-based DNA logic device on live cell membranes via associative toehold activation for accurate cancer cell identification. J. Am. Chem. Soc. 141, 12738–12743 (2019).
Google Scholar
Zhang, C. et al. Cancer diagnosis with DNA molecular computation. Nat. Nanotechnol. 15, 709–715 (2020).
Google Scholar
Benenson, Y., Gil, B., Ben-Dor, U., Adar, R. & Shapiro, E. An autonomous molecular computer for logical control of gene expression. Nature 429, 423–429 (2004).
Google Scholar
Douglas, S. M., Bachelet, I. & Church, G. M. A logic-gated nanorobot for targeted transport of molecular payloads. Science 335, 831–834 (2012).
Google Scholar
Kim, K. T., Angerani, S., Chang, D. L. & Winssinger, N. Coupling of DNA circuit and templated reactions for quadratic amplification and release of functional molecules. J. Am. Chem. Soc. 141, 16288–16295 (2019).
Google Scholar
Emanuelson, C., Bardhan, A. & Deiters, A. DNA logic gates for small molecule activation circuits in cells. ACS Synth. Biol. 13, 538–545 (2024).
Google Scholar
Prinzen, A. L. et al. Amplified self-immolative release of small molecules by spatial isolation of reactive groups on DNA-minimal architectures. Angew. Chem. Int. Ed. 59, 12900–12908 (2020).
Google Scholar
Wang, D., Li, S. H., Zhao, Z. L., Zhang, X. B. & Tan, W. H. Engineering a second-order DNA logic-gated nanorobot to sense and release on live cell membranes for multiplexed diagnosis and synergistic therapy. Angew. Chem. Int. Ed. 60, 15816–15820 (2021).
Google Scholar
Li, S. P. et al. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger. Nat. Biotechnol. 36, 258–264 (2018).
Google Scholar
Dockerill, M. et al. Development of supramolecular anticoagulants with on-demand reversibility. Nat. Biotechnol. 43, 186–193 (2025).
Google Scholar
Yu, H. X. et al. Aptameric hirudins as selective and reversible EXosite-ACTive site (EXACT) inhibitors. Nat. Commun. 15, 3977 (2024).
Google Scholar
Tolmachev, V. et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR In-DOTA-Z Affibody molecule: aspect of the injected tracer amount. Eur. J. Nucl. Med. Mol. I. 37, 613–622 (2010).
Google Scholar
Ang, Y. S., Qiu, X. Z., Yam, H. M., Wu, N. J. & Yung, L. Y. L. Enzyme-free and isothermal discrimination of microRNA point mutations using a DNA split proximity circuit with turn-on fluorescence readout. Biosens. Bioelectron. 217, 114727 (2022).
Google Scholar
He, A. X. et al. Structure- based investigation of a DNA aptamer targeting PTK7 reveals an intricate 3D fold guiding functional optimization. Proc. Natl Acad. Sci. USA 121, E2404060121 (2024).
Google Scholar
Shangguan, D. et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl Acad. Sci. USA 103, 11838–11843 (2006).
Google Scholar
Doronina, S. O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778–784 (2003).
Google Scholar
Li, W. et al. Synthesis and evaluation of camptothecin antibody-drug conjugates. ACS Med. Chem. Lett. 10, 1386–1392 (2019).
Google Scholar
Melkko, S., Dumelin, C. E., Scheuermann, J. & Neri, D. On the magnitude of the chelate effect for the recognition of proteins by pharmacophores scaffolded by self-assembling oligonucleotides. Chem. Biol. 13, 225–231 (2006).
Google Scholar
Ranallo, S., Prévost-Tremblay, C., Idili, A., Vallée-Bélisle, A. & Ricci, F. Antibody-powered nucleic acid release using a DNA-based nanomachine. Nat. Commun. 8, 15150 (2017).
Google Scholar
Kato, K. et al. Model for the complex between protein-G and an antibody Fc fragment in solution. Structure 3, 79–85 (1995).
Google Scholar
Dannenfelser, R. et al. Discriminatory power of combinatorial antigen recognition in cancer T cell therapies. Cell Syst. 11, 215–228 (2020).
Google Scholar
Maruani, A. et al. A plug-and-play approach to antibody-based therapeutics a chemoselective dual click strategy. Nat. Commun. 6, 6645 (2015).
Google Scholar
Strop, P. et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat. Biotechnol. 33, 694–696 (2015).
Google Scholar
Levengood, M. R. et al. Orthogonal cysteine protection enables homogeneous multi-drug antibody-drug conjugates. Angew. Chem. Int. Ed. 56, 733–737 (2017).
Google Scholar
Kumar, A. et al. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads. Bioorg. Med. Chem. Lett. 28, 3617–3621 (2018).
Google Scholar
Yamazaki, C. M. et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat. Commun. 12, 3528 (2021).
Google Scholar
Journeaux, T. & Bernardes, G. J. L. Homogeneous multi-payload antibody-drug conjugates. Nat. Chem. 16, 854–870 (2024).
Google Scholar
Liu, B. et al. Antibody–bottlebrush conjugates unlock diverse payloads for targeted cancer therapy. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02772-z (2025).
Google Scholar
Andreev, J. et al. Bispecific antibodies and antibody-drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol. Cancer Ther. 16, 681–693 (2017).
Google Scholar
Dong, Y. J. et al. Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J. Immunother. Cancer 12, e009710 (2024).
Google Scholar
Ma, Y. X. et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody- drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 25, 901–911 (2024).
Google Scholar
Liu, Y. S. et al. Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and Protein Tyrosine Kinase 7 as signatures for tumor aggressiveness. Mol. Cell. Proteomics 13, 1753–1768 (2014).
Google Scholar
Maitland, M. L. et al. First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody-drug conjugate targeting Protein Tyrosine Kinase 7, in advanced solid tumors. Clin. Cancer Res. 27, 4511–4520 (2021).
Google Scholar
Dessaux, C., Ganier, L., Guiraud, L. & Borg, J. P. Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer. Oncogene 43, 1973–1984 (2024).
Google Scholar
Oostindie, S. C. et al. Logic-gated antibody pairs that selectively act on cells co-expressing two antigens. Nat. Biotechnol. 40, 1509–1519 (2022).
Google Scholar
Pedram, K. et al. Design of a mucin-selective protease for targeted degradation of cancer-associated mucins. Nat. Biotechnol. 42, 597–607 (2024).
Google Scholar
Gunnoo, S. B. et al. Creation of a gated antibody as a conditionally functional synthetic protein. Nat. Commun. 5, 4388 (2014).
Google Scholar
Lajoie, M. J. et al. Designed protein logic to target cells with precise combinations of surface antigens. Science 369, 1637–1643 (2020).
Google Scholar
Kofoed, C. et al. Programmable protein ligation on cell surfaces. Nature 645, 793–800 (2025).
Google Scholar
Dovgan, I. et al. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and potency. Sci. Rep. 10, 7691 (2020).
Google Scholar
Mrcher, A., Nijenhuis, M. A. D. & Gothelf, K. V. A wireframe DNA cube: antibody conjugate for targeted delivery of multiple copies of monomethyl auristatin E. Angew. Chem. Int. Ed. 60, 21691–21696 (2021).
Google Scholar
Urata, H., Shinohara, K., Ogura, E., Ueda, Y. & Akagi, M. Mirror-image DNA. J. Am. Chem. Soc. 113, 8174–8175 (1991).
Google Scholar
Damha, M. J., Giannaris, P. A. & Marfey, P. Antisense L/D-oligodeoxynucleotide chimeras—nuclease stability, base-pairing properties, and activity at directing ribonuclease-H. Biochemistry 33, 7877–7885 (1994).
Google Scholar
Schaudy, E., Somoza, M. M. & Lietard, J. l-DNA duplex formation as a bioorthogonal information channel in nucleic acid-based surface patterning. Chem. Eur. J. 26, 14310–14314 (2020).
Google Scholar
Shearer, V., Yu, C. H., Han, X. & Sczepanski, J. T. The clinical potential of L-oligonucleotides: challenges and opportunities. Chem. Sci. 15, 18239–18258 (2024).
Google Scholar
Zhou, L. J. et al. Self-assembled L-DNA linkers for rapid construction of multi-specific antibody-drug conjugates library. Angew. Chem. Int. Ed. 62, e202302805 (2023).
Google Scholar
Kazane, S. A. et al. Self-assembled antibody multimers through peptide nucleic acid conjugation. J. Am. Chem. Soc. 135, 340–346 (2013).
Google Scholar
Shangguan, D. H., Cao, Z. H. C., Li, Y. & Tan, W. H. Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin. Chem. 53, 1153–1155 (2007).
Google Scholar
Kratschmer, C. & Levy, M. Effect of chemical modifications on aptamer stability in serum. Nucleic Acid Ther. 27, 335–344 (2017).
Google Scholar
Han, Y. Q. et al. Molecular programming design of glyconucleic acid aptamer with high stability. Adv. Sci. 12, 2408168 (2024).
Google Scholar
Zhang, Q. et al. Aptamer-based nongenetic reprogramming of CARs enables flexible modulation of T cell-mediated tumor immunotherapy. ACS Cent. Sci. 10, 813–822 (2024).
Google Scholar
Skaanning, M. K. et al. Self-assembly of ultrasmall 3D architectures of (L)-acyclic threoninol nucleic acids with high thermal and serum stability. J. Am. Chem. Soc. 146, 20141–20146 (2024).
Google Scholar
Chalker, J. M., Bernardes, G. J. L., Lin, Y. A. & Davis, B. G. Chemical modification of proteins at cysteine: opportunities in chemistry and biology. Chem. Asian J. 4, 630–640 (2009).
Google Scholar
Bernardim, B. et al. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents. Nat. Commun. 7, 13128 (2016).
Google Scholar
Walsh, S. J. et al. Site-selective modification strategies in antibody-drug conjugates. Chem. Soc. Rev. 50, 1305–1353 (2021).
Google Scholar
Ochtrop, P. et al. Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent PK profile. Chem. Sci. 14, 2259–2266 (2023).
Google Scholar
Honarvar, H. et al. Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors. Theranostics 6, 93–103 (2016).
Google Scholar
Oroujeni, M. et al. Affibody-mediated PNA-based pretargeted cotreatment improves survival of trastuzumab-treated mice bearing HER2-expressing xenografts. J. Nucl. Med. 63, 1046–1051 (2022).
Google Scholar
Yan, J. X. et al. Radionuclide therapy of bevacizumab-based PNA-mediated pretargeting. Nucl. Med. Commun. 45, 901–909 (2024).
Google Scholar
Chen, S.-K. et al. DNA-drug conjugates (DDCs) for computed delivery. Zenodo https://doi.org/10.5281/zenodo.17293902 (2026).
